key: cord-0742632-e6sqn5cr
authors: Glorion, M.; De Wolf, J.; Zuber, B.; Cassiano, F.; Preau, S.; Brun, AL.; Cohen, J.; Tachon, G.; Neuville, M.; Brugière, O.; Picard, C.; Beaumont-Azuar, L.; Fessler, J.; Jacqmin, S.; Pricopi, C.; Chapelier, A.; Cuquemelle, E.; Parquin, F.; Magnan, A.; Roux, A.; Le Guen, M.; Sage, S.; Cerf, C.
title: Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient.
date: 2021-08-08
journal: Respir Med Res
DOI: 10.1016/j.resmer.2021.100851
sha: 8d850eaa14394e01e6958106cb412c48791ab487
doc_id: 742632
cord_uid: e6sqn5cr

nan

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since December 2019. Despite optimized medical treatment, 6% to 10% of patients with end-stage COVID-19 pneumonia progress to acute respiratory distress syndrome (ARDS) requiring mechanical ventilation in 5% to 12% and ECMO support in less than 0,5% (1) (2) .

The place of lung transplantation (LT) as a therapeutic option has rarely been reported in ARDS and even less for COVID-19. Only a few cases have been reported in this setting (3, 4) (5) (6). The candidate selection and the timing of the LT procedure remains very questionable.

We report the first French case of lung transplantation for a patient affected by COVID-19 pneumonia with refractory ARDS and irreversible lung destruction.

On September 15th 2020, a 59-year-old man was admitted for dyspnea with a positive SARS-Cov2 nasopharyngeal swab in real time RT-PCR. The patient was a non-smoker with an uneventful medical history, except for a body mass index (BMI) of 30 kg/m 2 . On first examination respiratory frequency was 30/min, oxygen arterial saturation was 85% with a partial arterial pressure of oxygen of 52 mmhg with ambient air. He was immediately transferred to the ICU and treated with non-invasive ventilation. He received Dexamethasone (6 mg /24 h from day 2 to 10). The patient was intubated at day 5. Despite prone positioning, the patient was referred to the regional centre to benefit from a venovenous femoro-jugular ECMO (25 French and 19 French, Quadrox I Adult Getinge  , blood flow 5l/min and sweep gas flow 6l/min FiO2 100%).

On day 17, lung CT scan showed persistent bilateral, symmetrical pulmonary opacification with anteroposterior gradient, including dense consolidation in the dependant areas and ground glass opacities in the non-dependant lung consistent with early ARDS (Figure 1 ).

Following negativisation of SARS-Cov2 RT-PCR and morphological CT Scan evolution with worsening ground glass opacities associated with reticulations in the non-dependant regions a treatment with Methylprednisolone bolus of 1 g for 3 days was started on day 27. On day 37, he remained fully dependent on the VV ECMO support. Clinically, lung compliance was poor (10ml/cmH20) and imagery revealed partial resolution of the ground glass opacities, coarse reticular pattern in the anterior aerated lung with traction bronchiectasis suggesting underlying fibrosis, multiple small and coalescent pulmonary cysts probably related to prolonged ventilation and no sign of pulmonary embolism (Figure 1 ).

Considering the onset of such irreversible morphological patterns despite maximal treatment, LT was considered as an option and discussed with our team. At that time, there was no extra-respiratory failure. Echocardiography showed normal heart function with a left ventricular ejection fraction of 70% and no pulmonary hypertension. Kidney, liver, and haematological functions were also normal. After a temporary sedation diminution, the patient was responding to simple orders. Nevertheless, a severe ICU acquired tetra-paresis was noted. A brain CT scan showed no evidence of intracerebral haemorrhage or ischaemic events. After this short evaluation, sedation had to be continued because of the severe respiratory failure. During this period, the patient developed three ventilator-associated pneumonias with bacteraemia involving Staphylococcus aureus, Enterobacter aerogenes and Citrobacter koseri successfully treated by antibiotics.

A videoconference between the patient' family and the lung transplant team was held to explain risks and benefits. The patient was transferred to Foch hospital for complete assessment at day 42. A PET CT scan (18F fdg) and a coronary angiography were performed and did not find any particularity. The final team decision to perform a LT was based on the five considerations: irreversible lung destruction under maximal support, single organ failure, patient without underlying disease, no more SARS-COV2 replication (Two successive BAL specimen negative RT-PCR), t ' f m ed informed consent for LT. At day 43, the patient was listed on the high emergency lung transplant (HELT) program, according

to French regulations to prioritize graft allocation to patients with short-term severe prognoses (7) .

A sequential bilateral lung transplantation was performed at day 45. The surgical approach was a double anterolateral thoracotomy. VV ECMO was switched to a VVA ECMO which is our routine clinical practice. Central cannulation in the ascending aorta was performed through right thoracotomy. Femoral and jugular cannulas were used for venous drainage.

We used the standardized anaesthetic management previously described (8) .

Haemodynamic monitoring was done by continuous transoesophageal echography.

Explantation was challenging due to the fragility of the tissues and bleeding. Ten blood packs, 2 platelet units and 8 fresh frozen plasma packs were transfused. At the end of the procedure, despite a chest Xray ( Figure 2 ) showing moderate infiltrates, lack of oedema during bronchoscopy and good heart function the patient remained hypoxic. For this reason, Central VVA ECMO was switched to peripheral femoro-jugular VV ECMO just in backup. The VV ECMO was weaned on POD 2 and primary graft dysfunction grading at 72 h was 0. An early percutaneous tracheostomy was performed at POD 5 to help ventilation weaning. The first neuromuscular evaluation was done on POD 11 and showed severe neuromyopathy.

The neuromuscular MRC sum score was quoted as 3/60 (9) . Then an intensive physiotherapy program was started. He was sitting on POD 9 and started walking on POD 39 (MRC sum 34).

No specific alloimmunization was identified. Basiliximab induction and triple immunosuppression was initiated, including tacrolimus, mycophenolate mofetil, and steroids. Systematic lung biopsy following our protocol (10) Of note, native lung specimens were pathologically examined ( Figure 4 ). The lung architecture was globally preserved with lesions that were temporally and geographically homogenous and suggestive of a fibrotic histological pattern without necrosis or thrombosis.

Here we describe the first French case of LT due to irreversible ARDS associated with COVID- 19 . To date, a few cases have already been published in China (5) (3), USA (11) and Austria (4) .

Acute respiratory insufficiency is not a classical indication for pulmonary transplantation.

However, ARDS management has considerably changed in the last decade thanks to the possibilities of respiratory assistance by extracorporeal life support (ECLS). This strategy allows support for lung dysfunction and gives time for the lung to heal. Several patients have been weaned after extended periods (12) . However, prolonged ECMO is an invasive therapy that exposes the patients to many risks or complications which can be life-threatening. Ethical considerations are a major concern in this situation of ARDS because the possibilities of spontaneous lung healing are very unpredictable and fatal complications after 30 days of ECMO assistance are frequent. However, some patients are stabilized on ECMO with irreversible lung damage and without other organ dysfunction. For them LT should be a salvage therapy but challenging, with outcomes poorly known and a dilemma considering the shortage of suitable donors and standard recipients on the waiting list whose results could be better (21) . These considerations highlight two major points: first, to recognize the irreversible nature of the lung injury; second, to find the compromise between the moment when the lung lesions are irreversible and the moment when prolonged ECMO and ICU complication preclude the feasibility of LT.

In our case, radiologically, the initial ground glass opacities and condensation moved on to a fibrosis pattern despite high dose steroid treatment. This made us consider progression towards a non-reversible nature of the lung damage. This was confirmed by histological examination with air space enlargement, fibrosis without thrombosis. We note that this patterns were very different from the Austrian case where they observed necrosis and thrombosis (4).

Neurological evaluation was challenging in this specific disease. In this report, a short awakening testing and brain CT scan were possible. In case of neurologic doubt, functional imagery could be interesting but VV ECMO does not allow this strategy and brain CT probably remains the best solution. Moreover, the assessment of the muscles (strength, mass) is crucial before LT. As noted by Cypel et al. physical rehabilitation on an ECMO bridge improves outcomes in such patients (22) . But here, it appeared to be non-feasible according to the deepness of hypoxaemia.

The severe ICU-acquired paralysis and malnutrition were a considerable challenge for postoperative rehabilitation and mechanical ventilation weaning (23) . Good early graft function allowed an aggressive physiotherapeutic and nutritional program, and we observed a rapid improvement of MRC score. At discharge he had remarkable lung function and he was fully autonomous for walking.

According to ISHLT 2006, potential candidates should be well informed and demonstrate adequate healthy behavior and a willingness to adhere to guidelines from health care professionals (24) . Due to the patient's clinical status, it was not possible for him to sign informed consent. According to French law in case of emergency, his wife, after being well informed about the risks and benefits, gave consent for him to be treated.

During the surgery, the dissection showed significant tissue fragility and bleeding related to coagulopathy of prolonged ECMO as previously described (4) . We usually advocate femoral VA ECMO support because it has several advantages in our practice, including an ability to provide optimal respiratory and hemodynamic support. In this way, ECMO allows a partial bypass of the pulmonary circulation and then decreases mechanical shear stress, pulmonary reperfusion and pressure which are recognized as PGD risk factors. In this case, with destruction of the lung, we chose a central cannulation for the artery to avoid Harlequin syndrome.

Our case indicates that lung transplantation may be a dedicated option for strictly selected patients with refractory ARDS secondary to SARS-COV2 disease. Also, this pandemic condition creates a momentum to consider a high selective indication of LT in acute lung disease. A: chronic scarring with architectural destruction in the form of a microcystic appearance (black arrows) of the pulmonary parenchyma due to dilated alveolar spaces.

B: significant vascular changes with a significant amount of new vessel growth and fibrous and oedematous thickening of the media (black arrows) with very few thrombi. Interstitial fibrosis (red arrow).

C: traction bronchiectasis (black arrow) with peribronchiolar metaplasia (red arrow) and vascular changes with fibrosis thickening of small vessel walls (blue arrow).

D: interstitial fibrosis (red arrow) with mild to moderate interstitial inflammation composed of lymphocytes and plasma cells. Type II hyperplasia of the pneumocytes (black arrow).

Clinical Characteristics of Coronavirus Disease 2019 in China

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. The Lancet Respiratory

Lung Transplantation for Elderly Patients With End-Stage COVID-19 Pneumonia

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. The Lancet Respiratory

High Emergency Lung Transplantation: dramatic decrease of waiting list death rate without relevant higher post-transplant mortality

Inhaled nitric oxide dependency at the end of double-lung transplantation: a boosted propensity score cohort analysis

Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome

Évolution et progrès en transplantation pulmonaire : étude de la cohorte de 600 premiers patients transplantés pulmonaires à l'hôpital Foch

Lung transplantation for patients with severe COVID-19

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

Emergency lung transplantation after extracorporeal membrane oxygenation

Double lung transplantation for adult respiratory distress syndrome after recombinant interleukin 2

Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning

Lung transplantation following 107 days of extracorporeal membrane oxygenation

Lung Transplantation After 125 Days on ECMO for Severe Refractory Hypoxemia With No Prior Lung Disease

Lung Transplantation for the Treatment of Irreversible Acute Respiratory Distress Syndrome

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. The Lancet Respiratory

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. The Lancet

Beware the Deus Ex Machina of COVID-19

When to consider lung transplantation for COVID-19. The Lancet Respiratory

Does ICUacquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med

International guidelines for the selection of lung transplant candidates